SCHEMBL17796995

SCHEMBL17796995

Cc1ccc(-c2ccccc2C(=O)O)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 1/20 0.53
MCL1 Q07820 1/20 0.53
MYC P01106 1/20 0.51
KMO O15229 2/20 0.51
AKR1C2 P52895 3/20 0.50
AKR1C3 P42330 2/20 0.50
LTB4R2 Q9NPC1 1/20 0.49
DHODH Q02127 3/20 0.48
AKR1C1 Q04828 2/20 0.48
AKR1B10 O60218 1/20 0.48
AKR1C4 P17516 1/20 0.48
LDHA P00338 1/20 0.46
PTPN11 Q06124 1/20 0.46
NR1I2 O75469 1/20 0.45
CYP2C9 P11712 1/20 0.45
IDO1 P14902 1/20 0.45
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269897 0.85 MCL1 (0.57) ACMSDMCL1MYCLTB4R2LDHA
SCHEMBL20099815 0.83 MAPT (0.44) MYCKMODHODHLDHAUSP2
SCHEMBL10024262 0.81 ACMSD (0.69) ACMSDMCL1AKR1C2DHODHAKR1C1
SCHEMBL4651517 0.81 MCL1 (0.65) ACMSDMCL1MYCAKR1C2AKR1C3
SCHEMBL23354547 0.81 FTO (0.53) MCL1MYCKMOAKR1C2AKR1C1
SCHEMBL4602451 0.80 PTGS2 (0.56) ACMSDMCL1LTB4R2DHODHPTPN11
SCHEMBL489515 0.80 SLC6A3 (0.47) KMOAKR1C2AKR1C3AKR1C1AKR1B10
SCHEMBL12918620 0.80 SLC6A3 (0.47) ACMSDKMOAKR1C2AKR1C3AKR1C1
SCHEMBL5151025 0.80 ACMSD (0.50) ACMSDMYCAKR1C2LTB4R2DHODH
SCHEMBL5103351 0.78 ERN1 (0.58) MCL1MYCKMODHODHPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
CN-110862368-B Photocatalytic oxidation synthesis method of benzocoumarin compound 浙江工业大学 2021-06-15 CN disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed
CN-110862368-A Photocatalytic oxidation synthesis method of benzocoumarin compound 浙江工业大学 2020-03-06 CN disclosed
EP-3029026-B1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME DONG A ST CO LTD (KR) 2018-12-05 EP disclosed
EP-3029026-A1 NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME Dong-A ST Co., Ltd. (KR) 2016-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 ACMSD 724/4885MCL1 3739/4885MYC 4787/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 ACMSD 724/4885MCL1 3739/4885MYC 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.